• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Ventyx Biosciences Inc.

    5/30/25 7:01:07 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTYX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Ventyx Biosciences, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    92332V107

    (CUSIP Number)


    05/22/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    92332V107


    1Names of Reporting Persons

    Affinity Healthcare Fund, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,057,105.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,057,105.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,057,105.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.70 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    92332V107


    1Names of Reporting Persons

    Affinity Asset Advisors, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,057,105.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,057,105.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,057,105.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.70 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Ventyx Biosciences, Inc.
    (b)Address of issuer's principal executive offices:

    12790 El Camino Real Suite 200 San Diego, CA 92130
    Item 2. 
    (a)Name of person filing:

    Affinity Healthcare Fund, LP Affinity Asset Advisors, LLC
    (b)Address or principal business office or, if none, residence:

    450 Park Avenue Suite 1403 New York, NY 10022
    (c)Citizenship:

    Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC - Delaware
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    92332V107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Affinity Asset Advisors, LLC (the "Advisor") is the investment manager of Affinity Healthcare Fund, LP (the "Fund") and exercises investment discretion with regard to the securities reported herein. As of May 30, 2025, the Fund beneficially owned an aggregate of 4,057,105 shares of Common Stock of the Issuer, or 5.70% of the outstanding shares of Common Stock of the Issuer, and the Advisor may be deemed to be the beneficial owner of such 4,057,105 shares of Common Stock of the Issuer owned by the Fund by virtue of its position as investment manager of the Fund. The Fund and the Advisor have the shared power to vote or to direct the vote and to dispose or direct the disposition of 4,057,105 shares of Common Stock of the Issuer.
    (b)Percent of class:

    The percentage set forth in the preceding paragraph and in Row 11 of the cover page for each reporting person is based on 71,161,201 shares of Common Stock of the Issuer outstanding as of May 5, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 8, 2025.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Affinity Healthcare Fund, LP - 0 Affinity Asset Advisors, LLC - 0

     (ii) Shared power to vote or to direct the vote:

    Affinity Healthcare Fund, LP - 4,057,105 Affinity Asset Advisors, LLC - 4,057,105

     (iii) Sole power to dispose or to direct the disposition of:

    Affinity Healthcare Fund, LP - 0 Affinity Asset Advisors, LLC - 0

     (iv) Shared power to dispose or to direct the disposition of:

    Affinity Healthcare Fund, LP - 4,057,105 Affinity Asset Advisors, LLC - 4,057,105

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Affinity Healthcare Fund, LP
     
    Signature:/s/ Andrew Weinstein
    Name/Title:Andrew Weinstein
    Date:05/30/2025
     
    Affinity Asset Advisors, LLC
     
    Signature:/s/ Andrew Weinstein
    Name/Title:Andrew Weinstein
    Date:05/30/2025
    Get the next $VTYX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VTYX

    DatePrice TargetRatingAnalyst
    11/5/2025$18.00Neutral → Buy
    H.C. Wainwright
    3/12/2024$12.00Perform → Outperform
    Oppenheimer
    3/12/2024$7.00 → $16.00Equal Weight → Overweight
    Wells Fargo
    11/7/2023$46.00 → $6.00Overweight → Equal-Weight
    Morgan Stanley
    11/7/2023Outperform → Perform
    Oppenheimer
    11/7/2023Buy → Neutral
    H.C. Wainwright
    11/7/2023$6.00Buy → Hold
    Stifel
    11/7/2023$77.00 → $8.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $VTYX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gujrathi Sheila bought $300,573 worth of shares (130,000 units at $2.31) (SEC Form 4)

    4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)

    12/26/24 8:05:18 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO AND PRESIDENT Mohan Raju bought $959,889 worth of shares (500,000 units at $1.92), increasing direct ownership by 30% to 2,175,028 units (SEC Form 4)

    4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)

    11/25/24 9:07:34 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTYX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ventyx Biosciences upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Ventyx Biosciences from Neutral to Buy and set a new price target of $18.00

    11/5/25 7:25:28 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Biosciences upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Ventyx Biosciences from Perform to Outperform and set a new price target of $12.00

    3/12/24 7:35:44 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Biosciences upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Ventyx Biosciences from Equal Weight to Overweight and set a new price target of $16.00 from $7.00 previously

    3/12/24 7:35:12 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTYX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Forman Mark S was granted 3,000 shares, increasing direct ownership by 100% to 6,000 units (SEC Form 4)

    4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)

    11/19/25 4:30:10 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Senior VP, Finance Gonzales Roy was granted 1,767 shares, increasing direct ownership by 50% to 5,313 units (SEC Form 4)

    4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)

    11/19/25 4:30:03 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Cadoret-Manier Onaiza

    4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)

    6/6/25 3:11:56 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTYX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ventyx Provides Clinical and Corporate Updates

    Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical AdvisorExpanding the Phase 2 recurrent pericarditis study into Canada, EU and the UK to evaluate QD dose ranging in preparation for the global Phase 3 development planInterim analysis for the ongoing Phase 2 recurrent pericarditis study to now be presented as part of Ventyx's R&D Day planned for Q1 2026 SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerativ

    12/2/25 7:02:00 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference

    SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Piper Sandler 37th Annual Healthcare Conference in New York. Piper Sandler 37th Annual Healthcare Conference details:Fireside ChatDate: Wednesday, December 3, 2025Time: 4:00 – 4:25 PM ET A live webcast of the event will be available In the Investors and News section of the Ventyx website at https://ventyxbio.com/. A w

    12/1/25 7:02:00 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London

    SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference in London. Jefferies Global Healthcare Conference details:Fireside ChatDate: Wednesday, November 19, 2025Time: 11:00 – 11:25 AM GMT A webcast of the event will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be

    11/17/25 7:02:00 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTYX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Ventyx Biosciences Inc.

    SCHEDULE 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    11/14/25 4:07:07 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Ventyx Biosciences Inc.

    10-Q - Ventyx Biosciences, Inc. (0001851194) (Filer)

    11/6/25 4:10:49 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Ventyx Biosciences, Inc. (0001851194) (Filer)

    11/6/25 4:05:12 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTYX
    Financials

    Live finance-specific insights

    View All

    Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

    VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the first weekVTX3232 monotherapy reduced IL-6 levels at Week 12 below the threshold for cardiovascular risk of ≤1.65ng/L1Statistically significant reductions in Lp(a) and liver inflammationNo effect on weight either as a monotherapy or as add-on to semaglutide VTX3232 was safe and well tolerated both as a monotherapy and add-on to semaglutide in this studyVentyx to hold conference call and webcast 4:30pm ET on Wednesday, October 22nd SAN DIEGO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences,

    10/22/25 4:02:00 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress

    Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson's disease and in participants with obesity with certain additional cardiovascular risk factors Cash, cash equivalents and marketable securities of $302.6 million as of March 31, 2024 are expected to fund planned operations into at least the second half of 2026 Ventyx to host conference call and webcast today at 4:30PM ET SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medi

    5/9/24 4:01:00 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

    SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on May 9, 2024. Company management will host a conference call and webcast beginning at 4:30 p.m. ET/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress. To participate in the conference call, please dial (800) 343-4849 (U.S.) or (203) 518-9848 (international)

    5/2/24 4:05:00 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTYX
    Leadership Updates

    Live Leadership Updates

    View All

    Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

    Appointment of seven recognized experts is validating for Ventyx's NLRP3 Program--AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson's disease SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, today announced the appointment of seven additional internationally-recognized scientists and clinicians to its Scientific Advisory Board (SAB): Mo Lamkanfi, PhD, Luke O'Neill, PhD, Ted Dawson, MD, PhD, Martin Pomper, MD, PhD, Antonio Abbate, MD, PhD, Paul Cremer, MD

    4/1/25 7:00:00 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

    A Phase 2 obesity and cardiometabolic trial of VTX3232 and a Phase 2a trial of VTX3232 in patients with Parkinson's disease are both expected to initiate in H2 2024 A Phase 2 trial of VTX2735 in recurrent pericarditis is expected to initiate in H2 2024 Mark Forman, MD, PhD will join Ventyx as Chief Medical Officer effective August 12, 2024 Cash, cash equivalents and marketable securities of $279.7 million as of June 30, 2024 are expected to fund planned operations into at least the second half of 2026 SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapie

    8/8/24 4:01:00 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

    SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced the appointment of industry veteran Matthew Moore as Chief Operating Officer. "I am excited to welcome Matt to the Ventyx leadership team," said Raju Mohan, Chief Executive Officer. "He brings a wealth of expertise to Ventyx from his multiple decades in the biopharma industry. In his role as COO, Matt will play an important role in driving corporate operations, business development and strategy." "I am excited to

    5/16/24 8:00:00 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTYX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

    SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    11/14/24 7:54:08 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

    SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    11/14/24 3:06:49 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

    SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    11/14/24 8:57:39 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care